The Single-use Assemblies Market was valued at USD 13.47 billion in 2024, and is projected to reach USD 31.87 billion by 2030, rising at a CAGR of 16.24%. Life science companies are eager to avoid the cost and time of cleaning needed with stainless steel. The augmented expansion of the international biotech industries has offered a growth environment, in which novel, disposable technologies are becoming more significant. As pharmaceutical companies, distributors, CDMOs, and manufacturers converge around the benefits of single-use assemblies, the industry will grow at a faster pace during the forecast period. From therapies for rare diseases to cancer research, the impact of single-use technology in accelerating cutting-edge research into these conditions is set to grow, thereby propelling industry growth.
In addition, the growing biologics market will further offer lucrative opportunities during the study period. Eradicating the risk of contamination is the major challenge faced by biopharmaceutical manufacturers, which currently involves high-level monitoring of critical manufacturing solutions. Single-use assemblies support manufacturers in overcoming this difficulty by eliminating or reducing the necessity for sterilization between the batches, thereby filtering the operational capability. SUTs are considered one of the important areas of growth among biomanufacturing companies, as several biopharmaceutical companies are venturing into disposable assembly offerings for the production of all sorts of biopharmaceuticals.
Moreover, SUTs are now being heavily adopted for the clinical manufacturing of biopharmaceuticals and have become more conventional within commercial manufacturing facilities. SUTs permit biologics manufacturers to reduce the facilities' footprint by almost 20% due to the need for utilities, which generate steam, water, and clean-in-place solutions. Furthermore, as per the research by BioProcess International, the engineers estimated that the capital expenditure for the single-use facility is 25-45% less than for a facility established on stainless-steel equipment. Similarly, they also estimated that single-use facilities need half the energy and water during operations and can be built in 18 months. Whereas the stainless-steel facility takes three years. Owing to such advantages, the adoption of single-use assemblies is increasing, thereby driving industry growth.
In recent years, CMOs have been integrating single-use assemblies into most or all their bioprocess. CMOs broadly use single-use assemblies for quicker processing and process changeover time. The quick turnaround time and flexibility between process runs and various client projects allowed by single-use assemblies can enhance the CMO efficiency, which, in turn, aids in the reduction of the overall costs. In addition, the growing number of CMO facilities are essentially fully single-use. CMOs adoption of single-use technology can save on campaign and facility costs, which helps reduce the operating costs and capital investments. Furthermore, single-use assemblies in CMOs decrease the complexity and reduces lead times in upstream processes.
They also enhance the quality of products by preventing cross-contamination in downstream processes, especially for processes handling potent or toxic materials, such as antibody-drug conjugates and viral vectors. Moreover, stringent regulatory requirements in the manufacturing systems also endorse the adoption of single-use assemblies in CMOs.COVID-19 has augmented an already rapidly rising demand for single-use assemblies as the SUTs allow for the speedy production and development of therapies and vaccines and improve accuracy and time. For instance, Aramus single-use bag assembly developed by Entegris, Inc. was used for the storage of COVID-19 vaccines as the vaccines need extremely low temperatures to preserve. With low leachable and extractable and an extensive operating-temperature variety, the patented single-use bags were ideal for cold chain storage and collection.
In addition, key manufacturers are also accelerating investment projects or increasing their capital expenditures. For instance, Pall Corp., invested USD 114 million to upsurge its single-use output. These investments comprise additional manufacturing capacity at 6 current manufacturing facilities in the United States and Europe. Moreover, MilliporeSigma, Thermo Fisher, and Cytiva have also augmented growth plans to support the industry’s backlog. For instance, in March 2021 Merck announced the addition of a single-use assembly production unit at its Life Science Center in Molsheim, France. The investment of USD 26.25 million will accelerate the European expansion plans of the company for single-use products critical to manufacturing vaccines and lifesaving therapies. On the other hand, regulatory concerns due to leachable and extractable might hamper the growth of disposable assemblies in the forecast period.
Leachable and extractable are set of undesired impurities in the product stream, these are compounds that can move into the product from manufacturing systems, packaging containers, or other product-contact systems. Extractable is extracted from the contact materials under extreme conditions, such as treatment with a harsh solvent or elevated temperature conditions. Leachable compounds, on the other hand, are those that are leached into the final product from contact materials during normal or real-time storage conditions. North America dominated the global industry in 2023 due to the growth in the biotechnology and pharmaceutical industries, advancement in SUT products, and increasing incidence of diseases, such as cancer coupled with increasing investments and funding in drug discovery research. Asia-Pacific is expected to grow at a considerable CAGR over the forecast years owing to the strategic activities by key players coupled with funding by the government for biopharmaceutical R&D.
This product will be delivered within 2 business days.
In addition, the growing biologics market will further offer lucrative opportunities during the study period. Eradicating the risk of contamination is the major challenge faced by biopharmaceutical manufacturers, which currently involves high-level monitoring of critical manufacturing solutions. Single-use assemblies support manufacturers in overcoming this difficulty by eliminating or reducing the necessity for sterilization between the batches, thereby filtering the operational capability. SUTs are considered one of the important areas of growth among biomanufacturing companies, as several biopharmaceutical companies are venturing into disposable assembly offerings for the production of all sorts of biopharmaceuticals.
Moreover, SUTs are now being heavily adopted for the clinical manufacturing of biopharmaceuticals and have become more conventional within commercial manufacturing facilities. SUTs permit biologics manufacturers to reduce the facilities' footprint by almost 20% due to the need for utilities, which generate steam, water, and clean-in-place solutions. Furthermore, as per the research by BioProcess International, the engineers estimated that the capital expenditure for the single-use facility is 25-45% less than for a facility established on stainless-steel equipment. Similarly, they also estimated that single-use facilities need half the energy and water during operations and can be built in 18 months. Whereas the stainless-steel facility takes three years. Owing to such advantages, the adoption of single-use assemblies is increasing, thereby driving industry growth.
In recent years, CMOs have been integrating single-use assemblies into most or all their bioprocess. CMOs broadly use single-use assemblies for quicker processing and process changeover time. The quick turnaround time and flexibility between process runs and various client projects allowed by single-use assemblies can enhance the CMO efficiency, which, in turn, aids in the reduction of the overall costs. In addition, the growing number of CMO facilities are essentially fully single-use. CMOs adoption of single-use technology can save on campaign and facility costs, which helps reduce the operating costs and capital investments. Furthermore, single-use assemblies in CMOs decrease the complexity and reduces lead times in upstream processes.
They also enhance the quality of products by preventing cross-contamination in downstream processes, especially for processes handling potent or toxic materials, such as antibody-drug conjugates and viral vectors. Moreover, stringent regulatory requirements in the manufacturing systems also endorse the adoption of single-use assemblies in CMOs.COVID-19 has augmented an already rapidly rising demand for single-use assemblies as the SUTs allow for the speedy production and development of therapies and vaccines and improve accuracy and time. For instance, Aramus single-use bag assembly developed by Entegris, Inc. was used for the storage of COVID-19 vaccines as the vaccines need extremely low temperatures to preserve. With low leachable and extractable and an extensive operating-temperature variety, the patented single-use bags were ideal for cold chain storage and collection.
In addition, key manufacturers are also accelerating investment projects or increasing their capital expenditures. For instance, Pall Corp., invested USD 114 million to upsurge its single-use output. These investments comprise additional manufacturing capacity at 6 current manufacturing facilities in the United States and Europe. Moreover, MilliporeSigma, Thermo Fisher, and Cytiva have also augmented growth plans to support the industry’s backlog. For instance, in March 2021 Merck announced the addition of a single-use assembly production unit at its Life Science Center in Molsheim, France. The investment of USD 26.25 million will accelerate the European expansion plans of the company for single-use products critical to manufacturing vaccines and lifesaving therapies. On the other hand, regulatory concerns due to leachable and extractable might hamper the growth of disposable assemblies in the forecast period.
Leachable and extractable are set of undesired impurities in the product stream, these are compounds that can move into the product from manufacturing systems, packaging containers, or other product-contact systems. Extractable is extracted from the contact materials under extreme conditions, such as treatment with a harsh solvent or elevated temperature conditions. Leachable compounds, on the other hand, are those that are leached into the final product from contact materials during normal or real-time storage conditions. North America dominated the global industry in 2023 due to the growth in the biotechnology and pharmaceutical industries, advancement in SUT products, and increasing incidence of diseases, such as cancer coupled with increasing investments and funding in drug discovery research. Asia-Pacific is expected to grow at a considerable CAGR over the forecast years owing to the strategic activities by key players coupled with funding by the government for biopharmaceutical R&D.
Single-use Assemblies Market Report Highlights
- The filtration assemblies segment led the industry in 2024. Increased regulatory prospects and the need to diminish the risk of contamination have promoted the use of filtration assemblies for bulk and final fill operations
- The bag assemblies segment is expected to grow at a lucrative CAGR over the forecast period. Advantages, such as no need for validation or cleaning, lower shipping cost due to less weight, and low maintenance cost & capital investment drive the segment growth
- The customized solutions segment captured the highest revenue share in 2024. Several companies offer customized solutions to fast-track pharmaceutical manufacturing and drug development
- The pharmaceutical & biotechnological companies end-user segment led the global industry in 2024. The growth of the current manufacturing facilities for biopharmaceuticals drives the demand for single-use assemblies
- The CROs & CMOs segment is expected to grow at the fastest CAGR over the forecast period. In recent years, CMOs have been integrating single-use technology into most or all their bioprocess
- The quick turnaround time and flexibility between process runs and various client projects allowed by single-use equipment can enhance the CMO efficiency, which aids in the reduction of the overall costs
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Single-use Assemblies Market Variables and Trends
Chapter 4. Single-use Assemblies Market: Product Estimates & Trend Analysis
Chapter 5. Single-use Assemblies Market: Solution Estimates & Trend Analysis
Chapter 6. Single-use Assemblies Market: Application Estimates & Trend Analysis
Chapter 7. Single-use Assemblies Market: End Use Estimates & Trend Analysis
Chapter 8. Single-use Assemblies Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Single-use Assemblies market report include:- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Sartorius AG
- Danaher Corporation
- Avantor
- Lonza
- Saint-Gobain
- Corning Incorporated
- Entegris
- KUHNER AG
